Sequent Scientific and Viyash Life Sciences Secure Shareholder and Regulatory Approvals for ₹8,000-Crore Merger
Strategic Merger to Create a Global Pharmaceutical and Animal Health Leader
Sequent Scientific Ltd., a leading global animal health company, and Hyderabad-based Viyash Life Sciences have received overwhelming shareholder approval for their proposed merger valued at around ₹8,000 crore. This strategic union is poised to create a stronger, integrated pharmaceutical and animal health entity with a significant global footprint.
The merger plan was approved by an overwhelming 99.98% of Sequent’s public shareholders on August 30, 2025. In addition to shareholder consent, the companies have received all necessary regulatory clearances from the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The firms have now initiated the next step by filing for final approval with the National Company Law Tribunal (NCLT).
Under the merger terms, Viyash shareholders will receive 56 shares of Sequent for every 100 shares held. This will increase Sequent’s total share capital from 240 million to approximately 428 million shares. The promoter and promoter group’s stake in the merged entity will stand at roughly 62.4%.
The merger combines Sequent’s expertise in animal health with Viyash’s strengths in human healthcare, creating a diversified pharmaceutical powerhouse. The consolidated company will operate 15 to 16 manufacturing facilities, including nine approved by the US Food and Drug Administration (USFDA). This expansion is expected to result in a five-fold increase in research and development (R&D) talent and a nine-fold boost in USFDA-approved manufacturing capacity.
Industry experts believe this merger will significantly enhance Sequent’s financial profile, improving profitability and strengthening its competitive position in the global pharmaceutical market. The combined entity plans to leverage synergies across manufacturing, R&D, and market presence to drive innovation and growth.
With this merger, Sequent and Viyash are set to become key players in the global animal health and pharmaceutical sectors, unlocking new opportunities for innovation and expansion.